What is Plaque Psoriasis Phase 3 Study CP-690,550?

Category: Others

false

See also: Clinical Trial

NCT01186744 is a randomized, mixed-blind, parallel-group treatment withdrawal and re-treatment study in subjects with moderate to severe chronic plaque psoriasis. The drug CP-690,550 is also known as tofacitinib (formerly tasocitinib). Another study name is A3921111

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 0
Mild 0
None 1

Commonly reported side effects and conditions associated with Plaque Psoriasis Phase 3 Study CP-690,550

Side effect Patients
Adherence
Adherence Evaluations
Always 0
Usually 1
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 1
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 0
Cost per month
Cost per month Evaluations
$200+ 1
$100-199 0
$50-99 0
$25-49 0
< $25 0
Not specified 0
Last updated:
There are no evaluations for Plaque Psoriasis Phase 3 Study CP-690,550.